Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

852
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
852
Gastritis III: Clinical Manifestations and Management01:23

Gastritis III: Clinical Manifestations and Management

436
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
436
Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

514
Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
514
Acute Kidney Injury III: Clinical Manifestations01:29

Acute Kidney Injury III: Clinical Manifestations

81
Acute Kidney Injury (AKI) progresses through distinct clinical phases: the oliguric, diuretic, and recovery phases, each marked by unique manifestations and challenges.Oliguric Phase:The oliguric phase is the initial stage of AKI, typically lasting 10 to 14 days. This phase is marked by a significant reduction in urine output, usually less than 400 mL per day, indicating decreased kidney function. Fluid retention is a prominent feature, leading to symptoms such as edema, hypertension, and...
81
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

31
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
31
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

941
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
941

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

The Association of Alpha-1 Antitrypsin Deficiency and Arterial Aneurysms: An Update and Review.

Journal of clinical and translational hepatology·2026
Same authorSame journal

Dubin-Johnson and Rotor Syndromes: A Review and Update of Pathophysiological Mechanisms.

Journal of clinical and translational hepatology·2026
Same author

Congenital Portosystemic Shunts: A Review.

Journal of clinical and translational hepatology·2026
Same author

Analysis of Protein Binding to Liver Mitochondria by Horizontal Polyacrylamide Gel Electrophoresis Using a Converted Agarose Electrophoresis Unit.

Journal of clinical and translational hepatology·2026
Same author

Three-dimensional modeling of sensory nerve architecture and eosinophil and mast cell interactions in eosinophilic gastrointestinal disease.

Journal of leukocyte biology·2026
Same author

Dengue Viral Infection and Associated Liver Disease.

Journal of clinical and translational hepatology·2026

Related Experiment Video

Updated: Sep 4, 2025

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

16.1K

Statin-induced Liver Injury Patterns: A Clinical Review.

Leon D Averbukh1, Alla Turshudzhyan2, David C Wu2

  • 1Department of Medicine, Division of Gastroenterology-Hepatology, Allegheny Health Network, Pittsburgh, PA, USA.

Journal of Clinical and Translational Hepatology
|July 15, 2022
PubMed
Summary
This summary is machine-generated.

Statins, or HMG-CoA reductase inhibitors, are widely used drugs. While generally safe, they can rarely cause liver injury, often reversible upon discontinuation.

Keywords:
Autoimmune hepatitisCholestasisCholestatic liver injuryDrug-induced liver injuryHepatocellular liver injuryStatin

More Related Videos

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
07:03

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

1.0K
Murine Precision-Cut Liver Slices as an Ex Vivo Model of Liver Biology
12:36

Murine Precision-Cut Liver Slices as an Ex Vivo Model of Liver Biology

Published on: March 14, 2020

16.2K

Related Experiment Videos

Last Updated: Sep 4, 2025

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

16.1K
Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
07:03

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

1.0K
Murine Precision-Cut Liver Slices as an Ex Vivo Model of Liver Biology
12:36

Murine Precision-Cut Liver Slices as an Ex Vivo Model of Liver Biology

Published on: March 14, 2020

16.2K

Area of Science:

  • Pharmacology
  • Hepatology
  • Internal Medicine

Background:

  • Hydroxymethyl glutaryl coenzyme A (HMG-CoA) reductase inhibitors, known as statins, are globally prescribed for cardiovascular health.
  • Statins are generally safe but can lead to adverse effects, including elevated aminotransferases and, rarely, severe liver injury.
  • Statin-induced liver injury (SIL) can manifest as hepatocellular or cholestatic patterns, with hepatocellular injury being more common.

Purpose of the Study:

  • To review current evidence regarding statin-induced liver injury (SIL).
  • To examine the occurrence and patterns of statin-induced cholestasis.
  • To highlight diagnostic approaches for suspected SIL.

Main Methods:

  • Comprehensive literature review of studies on statin-induced liver injury.
  • Analysis of reported cases of hepatocellular and cholestatic liver injury associated with statin use.
  • Discussion of diagnostic methodologies, including medical history, laboratory tests, imaging, and causality assessment tools like the Roussel Uclaf Causality Assessment Method (RUCAM).

Main Results:

  • Statin-induced liver injury is uncommon and typically presents as hepatocellular dysfunction.
  • Cholestatic patterns of liver injury are less frequent but have been documented.
  • Most cases of severe liver injury are reversible upon cessation of the offending statin.

Conclusions:

  • Statins are associated with a low risk of liver injury, predominantly hepatocellular.
  • Prompt diagnosis and management, including statin withdrawal, are key to recovery.
  • Thorough patient evaluation with appropriate investigations is crucial for causality assessment in suspected SIL.